3,4-dihydroxyphenylacetic acid has been researched along with Bradykinesia in 6 studies
3,4-Dihydroxyphenylacetic Acid: A deaminated metabolite of LEVODOPA.
(3,4-dihydroxyphenyl)acetic acid : A dihydroxyphenylacetic acid having the two hydroxy substituents located at the 3- and 4-positions. It is a metabolite of dopamine.
dihydroxyphenylacetic acid : A dihydroxy monocarboxylic acid consisting of phenylacetic acid having two phenolic hydroxy substituents.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Behavioral deficits at the end of the 14-day dosing regime and on day 28 (i." | 1.40 | Intranasal administration of alpha-synuclein aggregates: a Parkinson's disease model with behavioral and neurochemical correlates. ( Davydova, TV; Fomina, VG; Gruden, MA; Kudrin, VS; Morozova-Roche, LA; Narkevich, VB; Sewell, RD; Wang, C, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gruden, MA | 1 |
| Davydova, TV | 1 |
| Narkevich, VB | 1 |
| Fomina, VG | 1 |
| Wang, C | 1 |
| Kudrin, VS | 1 |
| Morozova-Roche, LA | 1 |
| Sewell, RD | 1 |
| Sgadò, P | 1 |
| Viaggi, C | 1 |
| Pinna, A | 1 |
| Marrone, C | 1 |
| Vaglini, F | 1 |
| Pontis, S | 1 |
| Mercuri, NB | 1 |
| Morelli, M | 1 |
| Corsini, GU | 1 |
| Bajo-Grañeras, R | 1 |
| Ganfornina, MD | 1 |
| Martín-Tejedor, E | 1 |
| Sanchez, D | 1 |
| Dhanushkodi, A | 1 |
| Akano, EO | 1 |
| Roguski, EE | 1 |
| Xue, Y | 1 |
| Rao, SK | 1 |
| Matta, SG | 1 |
| Rex, TS | 1 |
| McDonald, MP | 1 |
| Hantraye, P | 1 |
| Brouillet, E | 1 |
| Ferrante, R | 1 |
| Palfi, S | 1 |
| Dolan, R | 1 |
| Matthews, RT | 1 |
| Beal, MF | 1 |
| Abe, K | 1 |
| Taguchi, K | 1 |
| Wasai, T | 1 |
| Ren, J | 1 |
| Utsunomiya, I | 1 |
| Shinohara, T | 1 |
| Miyatake, T | 1 |
| Sano, T | 1 |
6 other studies available for 3,4-dihydroxyphenylacetic acid and Bradykinesia
| Article | Year |
|---|---|
Intranasal administration of alpha-synuclein aggregates: a Parkinson's disease model with behavioral and neurochemical correlates.
Topics: 3,4-Dihydroxyphenylacetic Acid; Administration, Intranasal; alpha-Synuclein; Amyloid; Animals; Corpu | 2014 |
Behavioral, neurochemical, and electrophysiological changes in an early spontaneous mouse model of nigrostriatal degeneration.
Topics: 3,4-Dihydroxyphenylacetic Acid; Age Factors; Analysis of Variance; Animals; Behavior, Animal; Brain | 2011 |
Apolipoprotein D mediates autocrine protection of astrocytes and controls their reactivity level, contributing to the functional maintenance of paraquat-challenged dopaminergic systems.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Animals, Newborn; Apolipoproteins D; Apoptosis; Astrocytes; | 2011 |
A single intramuscular injection of rAAV-mediated mutant erythropoietin protects against MPTP-induced parkinsonism.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Dependovirus; Dopamine; Erythropoietin; Ge | 2013 |
Inhibition of neuronal nitric oxide synthase prevents MPTP-induced parkinsonism in baboons.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Disease Model | 1996 |
Stereoselective effect of (R)- and (S)-1-methyl-1,2,3,4-tetrahydroisoquinolines on a mouse model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Carbidopa; Cell Count; Disease Models, Animal; Dopamine; Do | 2001 |